Advertisement

Pharmaceutical Research

, Volume 21, Issue 10, pp 1862–1866 | Cite as

Comparative Effects on Intestinal Absorption in Situ by P-glycoprotein-Modifying HIV Protease Inhibitors

  • Martin Richter
  • N#x00F3;ra Gy#x00E9;m#x00E1;nt
  • Jos#x00E9;f Moln#x00E1;r
  • Andreas Hilgeroth
Article

Abstract

Purpose. P-glycoprotein (P-gp) is made responsible for the limited oral bioavailability of P-gp substrates like peptidic HIV protease inhibitors (PIs). With respect to combined application of two PIs in antiretroviral regimes, we first investigated the influences on intestinal saquinavir uptake using different PIs in in situ perfusion studies.

Methods. Perfusion experiments were carried out in three intestinal segments with P-gp substrates talinolol and saquinavir using fixed concentrations of PIs and with each varying concentrations in the jejunum and ileum. Furthermore, cellular uptake of fluorescent P-gp substrate rhodamine-123 and MRP-substrate carboxyfluorescein has each been quantified in P-gp and MRP-expressing cells by flow cytometry under co-adminstration of PIs.

Results. Increase of calculated permeabilities of P-gp-specific substrate talinolol was found under co-administration of both PIs, ritonavir and H17, with highest absorption rates in the ileal and colon segment. H17 proved to be a better P-gp inhibitor than ritonavir by resulting IC50 values and also in the cellular uptake of rhodamine. Similar increases of permeabilities in ileum and colon have also been found for saquinavir as P-gp as well as MRP-substrate with differences in the jejunal uptake, which was found higher for H17. Additional MRP-inhibitory activities of H17 were proved by increasing cellular uptake rates of carboxyfluorescein in MRP-expressing cells.

Conclusions. The investigated PIs were characterized as effective P-gp inhibitors in the intestinal absorption of P-gp substrates. H17 showed MRP-inhibitory effects that also favor intestinal drug absorption of corresponding substrates. With respect to combined therapeutic application of PIs, compounds like H17 raise hopes for improved bioavailability of poorly absorbed compounds.

absorption HIV protease inhibitor intestine perfusion P-glycoprotein 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    X. Wie, J. M. Decker, H. Lui, Z. Zhang, R. B. Arani, J. M. Kilby, M. S. Saag, X. Wu, G. M. Shaw, and J. C. Kappes. Emergence of resistant immunodeficiency virus type 1 in patients receiving fu-sion inhibitor (T-20) monotherapy. Antimicrob. Agents Che-mother. 46:1896–1905 (2002).Google Scholar
  2. 2.
    A. Hilgeroth. Dimeric 4-aryl-1,4-dihydropyridines: development of a third class of nonpeptidic HIV-1 protease inhibitors. Min. Rev. Med. Chem. 2:235–245 (2002).Google Scholar
  3. 3.
    R. B. Kim, M. F. Fromm, C. Wandel, B. Leake, A. J. J. Wood, and D. M. Roden. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 Protease inhibitors. J. Clin. Invest. 101:289–294 (1998).Google Scholar
  4. 4.
    L. Profite, V. A. Eagling, and D. J. Back. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. AIDS 13:1623–1627 (1999).Google Scholar
  5. 5.
    M. T. Huisman, J. W. Smit, H. R. Wiltshire, R. M. W. Hoetelmans, J. H. Beijnen, and A. H. Schinkel. P-Glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol. Pharmacol. 59:806–813 (2001).Google Scholar
  6. 6.
    J. Drewe, H. Gutmann, G. Fricker, M. Török, C. Beglinger, and J. Huwyler. HIV Protease inhibitor ritonavir: a more potent in-hibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem. Pharmacol. 57:1147–1152 (1999).Google Scholar
  7. 7.
    C. Leopold. HIV-protease inhibitors-an overview. Pharm. Uns. Zeit 30:234–239 (2001).Google Scholar
  8. 8.
    M. L. Newell. Mechanism and timing of mother-to-child trans-mission of HIV-1. AIDS 12:831–837 (1998).Google Scholar
  9. 9.
    G. Moyle and B. Gazzard. Current knowledge and future pros-pects for the use of HIV protease inhibitors. Drugs 51:701–712 (1996).Google Scholar
  10. 10.
    J. H. Lin, M. Chiba, I.-W. Chen, J. A. Nishime, F. A. Deluna, M. Yamazaki, and Y. J. Lin. Effect of dexamethasone on the intes-tinal first-pass metabolism of indinavir in rats: evidence of cyto-chrome P-450 A and P-glycoprotein induction. Drug Metab. Dis-pos. 27:1187–1193 (1999).Google Scholar
  11. 11.
    H. Spahn-Langguth, G. Baktir, A. Radschuweit, A. Okyar, B. Terhaag, P. Ader, A. Hanafy, and P. Langguth. P-glycoprotein transporters and the gastrointestinal tract: Evaluation of the po-tential in vivo relevance of in vitro data employing talinolol as model compound. Int. J. Clin. Pharmacol. Ther. 36:16–34 (1998).Google Scholar
  12. 12.
    H. Gutmann, G. Fricker, J. Drewe, M. Toeroek, and D. S. Miller. Interactions of HIV protease inhibitors with ATP-dependant drug export proteins. Mol. Pharmacol. 56:383–389 (1999).Google Scholar
  13. 13.
    A. Hanafy, P. Langguth, and H. Spahn-Langguth. Pretreatment with potent P-glycoprotein ligands my increase intestinal secre-tion in rats. Eur. J. Pharm. Sci. 12:405–415 (2001).Google Scholar
  14. 14.
    M. M. Cornwell, I. Pastan, and M. M. Gottesmann. Certain cal-cium channel blockers bind specifically to multidrug-resistant hu-man KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J. Biol. Chem. 262:2166–2170 (1987).Google Scholar
  15. 15.
    A. Hilgeroth, C. Dressler, S. Neuhoff, H. Spahn-Langguth, and P. Langguth. Dimeric 4-aryl-1,4-dihydropyridines as novel HIV-1 protease inhibitors-affinities to intestinal P-glycoprotein. Pharmazie 55:784–785 (2000).Google Scholar
  16. 16.
    R. Yumoto, T. Murakami, Y. Nakamoto, R. Hasegawa, J. Nagai, and M. Takano. Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds. J. Phar-macol. Experim. Therapeut. 289:149–155 (1999).Google Scholar
  17. 17.
    S. D. Flanagan, C. L. Cummins, M. Susanto, X. Liu, L. H. Taka-hashi, and L. Z. Benet. Comparison of furosemide and vinblas-tine secretion from cell lines overexpressing multidrug resistance protein (P-glycoprotein) and multidrug resistance-associated pro-teins (MRP1 and MRP2). Pharmacology 64:126–134 (2002).Google Scholar
  18. 18.
    M. P. Draper, R. L. Martell, and S. B. Levy. Indomethacin-mediated reversal of multidrug resistance and drug efflux in hu-man and murine cell lines overexpressing MRP, but not P-glycoprotein. Br. J. Cancer 75:810–815 (1997).Google Scholar

Copyright information

© Springer Science+Business Media, Inc. 2004

Authors and Affiliations

  • Martin Richter
    • 1
  • N#x00F3;ra Gy#x00E9;m#x00E1;nt
    • 2
  • Jos#x00E9;f Moln#x00E1;r
    • 2
  • Andreas Hilgeroth
    • 1
  1. 1.Department of Pharmaceutical ChemistryMartin-Luther-University Halle-WittenbergHalleGermany
  2. 2.Department of Medical MicrobiologyUniversity of SzegedDom t#x00E9;r 10Hungary

Personalised recommendations